Very recently, a genome-wide DNA methylation analysis revealed that HOXB9 DNA methylation was linked to intrinsic EGFR-TKI resistance and complementary to mutation profiling could discern whether lung adenocarcinoma patients would benefit from EGFR-TKI treatment [66]. This evidence concerns the gene HOXB9 and lung adenocarcinoma.